143 related articles for article (PubMed ID: 36429891)
1. Genetic Associations of
Chang SL; Yang PJ; Lin YY; Jiang YJ; Liu PI; Huang CL; Yang SF; Tang CH
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429891
[TBL] [Abstract][Full Text] [Related]
2. Potential Impacts of
Lee KL; Lai TC; Wang YC; Shih PC; Yang YC; Tsao TC; Liu TC; Wen YC; Chang LC; Yang SF; Chien MH
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33802737
[TBL] [Abstract][Full Text] [Related]
3. Visfatin Polymorphisms, Lifestyle Risk Factors and Risk of Oral Squamous Cell Carcinoma in a Cohort of Taiwanese Males.
Chen KJ; Hsieh MH; Lin YY; Chen MY; Lien MY; Yang SF; Tang CH
Int J Med Sci; 2022; 19(4):762-768. PubMed ID: 35582417
[TBL] [Abstract][Full Text] [Related]
4. The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
Zhang LJ; Li XQ; Wang CD; Zhuang L; Gong Q; Li SJ; Liu X; Dong H; Wang XC
Cancer Biother Radiopharm; 2018 Dec; 33(10):460-465. PubMed ID: 30256660
[No Abstract] [Full Text] [Related]
5. Associations of
Chang JH; Lai TC; Yang PJ; Shih PC; Yang YC; Lee KL; Liu TC; Tsao TC; Yang SF; Chien MH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126605
[TBL] [Abstract][Full Text] [Related]
6. The Relationship between Long Noncoding RNA H19 Polymorphism and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma.
Wang YC; Tsao SM; Li YT; Lee CY; Tsao TC; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33799753
[TBL] [Abstract][Full Text] [Related]
7. Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
Martínez Larrad MT; Corbatón Anchuelo A; Fernández Pérez C; Pérez Barba M; Lazcano Redondo Y; Serrano Ríos M;
PLoS One; 2016; 11(5):e0153976. PubMed ID: 27166797
[TBL] [Abstract][Full Text] [Related]
8. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Ooi SQ; Chan RM; Poh LK; Loke KY; Heng CK; Chan YH; Gan SU; Lee KO; Lee YS
Pediatr Obes; 2014 Apr; 9(2):81-91. PubMed ID: 23447513
[TBL] [Abstract][Full Text] [Related]
9. Correlation of E-cadherin gene polymorphisms and epidermal growth factor receptor mutation in lung adenocarcinoma.
Huang CY; Hsieh MJ; Liu TC; Chiang WL; Liu MC; Yang SF; Tsao TC
Int J Med Sci; 2018; 15(8):765-770. PubMed ID: 30008585
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
11. Effect of WW Domain-Containing Oxidoreductase Gene Polymorphism on Clinicopathological Characteristics of Patients with EGFR Mutant Lung Adenocarcinoma in Taiwan.
Li JP; Chang JT; Ju PC; Hsieh MH; Chao YH; Tsao TC; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948746
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
13. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
14. In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children.
Ooi DS; Ong SG; Heng CK; Loke KY; Lee YS
BMC Genomics; 2016 Nov; 17(1):974. PubMed ID: 27887573
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract][Full Text] [Related]
16. SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Zhang L; Li QX; Wu HL; Lu X; Yang M; Yu SY; Yuan XL
Ann Oncol; 2014 Aug; 25(8):1584-90. PubMed ID: 24928833
[TBL] [Abstract][Full Text] [Related]
17. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
18. Impact of LncRNA GAS5 Genetic Variants and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma Patients.
Hsieh MH; Wu YL; Tsao TC; Huang YW; Lin JC; Lee CY; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011604
[TBL] [Abstract][Full Text] [Related]
19. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
20. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
